Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopure Hemopure user fee

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA extends review period for Biopure's Hemopure (hemoglobin glutamer-250 bovine) by three months to review mid-May amendment, setting the user fee goal date at Aug. 29. Biopure characterizes the submission as "additional analyses of previously submitted data." Hemopure was submitted July 31, 2002 for the treatment of acutely anemic patients undergoing orthopedic surgery and for the elimination or reduction of red blood cell transfusions. The BLA contains clinical data from a U.S. Phase III orthopedic surgery trial and a non-U.S. Phase III non-cardiac surgery tria
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002287

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel